In vivo antitumor experiments showed that mice immunized with CD-gp100-hFTN exhibited the lowest tumor volume on day 21, with the maximum population of gp100-specific IFNγ+CD8+ T cells in splenocytes. The gene discussed is CD8A; the disease is neoplasm.